Retrospective on global pulmonary hypertension clinical trials: 1999-2021

Data are quite sparse on the comprehensive analyses of pulmonary hypertension (PH) clinical trials worldwide. Information including participating countries (developed or developing), intervention type, trial size, PH categories, sponsorship, study phase, design strategies, and participants' dem...

Full description

Saved in:
Bibliographic Details
Published in:Journal of thoracic disease 2023-06, Vol.15 (6), p.3372-3385
Main Authors: Zheng, Lu, Tan, Jun, Yan, Yi, Wang, Shang, Yuan, Ping, Wu, Cheng, Zhao, Yin-Tao, Yang, Hai-Bo, Nappi, Francesco, Tonelli, Adriano R, Wang, Lan, Hu, Qing-Hua, Jiang, Rong
Format: Article
Language:English
Subjects:
Original
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Data are quite sparse on the comprehensive analyses of pulmonary hypertension (PH) clinical trials worldwide. Information including participating countries (developed or developing), intervention type, trial size, PH categories, sponsorship, study phase, design strategies, and participants' demographic characteristics was extracted from PH trials registered on ClinicalTrials.gov from 1999 to 2021. A total of 203 eligible clinical PH trials were screened, involving 23,402 participants, 67.8% of whom were females. Major clinical trials were designed to test drug interventions (95.6%), sponsored solely by industries in 59.5%, and targeting Group 1 PH patients in 76.3%. A large number of countries participated in PH clinical trials; however, most clinical trials were conducted in developed countries (84.2%). Developing countries were involved in clinical trials with larger sample sizes (P
ISSN:2072-1439
2077-6624
DOI:10.21037/jtd-23-701